Quest Diagnostics is experiencing a durable post-pandemic volume recovery, with revenue growth accelerating to 10.2% YoY in Q2 2026 and EPS growth of 15.0%, driven by disciplined cost management and operating leverage. The company's stable gross margin of 33.7...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 10.2% YoY in Q2 2026, with EPS up 15.0%, while gross margin held at 33.7% and operating margin expanded to 15.1% from 14.8% a year earlier.
Quest Diagnostics reported higher sales and earnings in Q4 2025 and Q1 2026, with 9.2% YoY revenue growth and 13% adjusted EPS growth, driven by organic growth and productivity gains.
The company issued 2026 guidance projecting US$11.70-US$11.82 billion in revenue and US$9.45-US$9.65 in diluted EPS, indicating confidence in continued growth.
Quest Diagnostics raised its quarterly dividend, signaling strong cash flow and commitment to returning capital to shareholders.
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 23, 2026 | $3.12+10.6% vs $2.82 | $3.0B+2.4% vs $3.0B |
Q2 2026 Apr 21, 2026 | $2.50+5.5% vs $2.37 | $2.9B+2.3% vs $2.8B |
Q1 2026 Feb 10, 2026 | $2.42+2.5% vs $2.36 | $2.8B+1.9% vs $2.8B |
Q4 2025 Oct 21, 2025 | $2.60+4.0% vs $2.50 | $2.8B+2.9% vs $2.7B |
Quest Diagnostics NYSE: DGX CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions.
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to those without. SECAUCUS, N.J.
Corient Private Wealth LP decreased its position in Quest Diagnostics Incorporated (NYSE: DGX) by 13.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,092 shares of the medical research company's stock after selling 5,233 shares during the period. Corient Private Wealth
Fed hikes rates and signals another, putting MGEE, ADM, DOLE and DGX in focus as low-beta defensive picks.
Benchmark DGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Quest Diagnostics Incorporated (DGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $236.44 | $26.1B | 27.02 | 11.78% | 8.99% | 13.99% | 1.32% | |
| $308.95 | $25.33B | 29.54 | 7.25% | 6.99% | 11.55% | — | |
| $53.01 | $2.76B | 135.92 | — | 33.7% | 22.86% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $387.54 | $10.43B | 13.91 | 0.65% | 8.59% | 3.15% | — | |
| $13.66 | $2.97B | -341.50 | -2.71% | -0.91% | -0.37% | — |
Quest Diagnostics Incorporated (DGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Quest Diagnostics Incorporated (DGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
May 21, 2026·SEC
May 8, 2026·SEC
Get notified when DGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Quest Diagnostics Incorporated (DGX) stock FAQ — growth, dividends, profitability & financials explained
Quest Diagnostics Incorporated (DGX) reported $11.56B in revenue for fiscal year 2025. This represents a 615% increase from $1.62B in 1996.
Quest Diagnostics Incorporated (DGX) grew revenue by 11.8% over the past year. This is steady growth.
Yes, Quest Diagnostics Incorporated (DGX) is profitable, generating $1.06B in net income for fiscal year 2025 (9.0% net margin).
Yes, Quest Diagnostics Incorporated (DGX) pays a dividend with a yield of 1.32%. This makes it attractive for income-focused investors.
Quest Diagnostics Incorporated (DGX) has a return on equity (ROE) of 14.0%. This is reasonable for most industries.
Quest Diagnostics Incorporated (DGX) generated $1.22B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
